US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US6893625B1
(en)
*
|
1986-10-27 |
2005-05-17 |
Royalty Pharma Finance Trust |
Chimeric antibody with specificity to human B cell surface antigen
|
IL85035A0
(en)
*
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
US7247475B2
(en)
*
|
1989-07-28 |
2007-07-24 |
Wyeth |
Method for producing monoclonal antibodies
|
US6475787B1
(en)
|
1989-07-28 |
2002-11-05 |
Wyeth |
Method for producing monoclonal antibodies
|
GB9020282D0
(en)
*
|
1990-09-17 |
1990-10-31 |
Gorman Scott D |
Altered antibodies and their preparation
|
GB9022543D0
(en)
*
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
GB9022545D0
(en)
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Culture medium
|
US6407213B1
(en)
|
1991-06-14 |
2002-06-18 |
Genentech, Inc. |
Method for making humanized antibodies
|
US6800738B1
(en)
*
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
GB9122820D0
(en)
*
|
1991-10-28 |
1991-12-11 |
Wellcome Found |
Stabilised antibodies
|
GB9125768D0
(en)
*
|
1991-12-04 |
1992-02-05 |
Hale Geoffrey |
Therapeutic method
|
DE4314556A1
(de)
*
|
1993-05-04 |
1994-11-10 |
Behringwerke Ag |
Modifizierte Antikörperenzymkonjugate und Fusionsproteine sowie ihre Anwendung zur tumorselektiven Therapie
|
GB9424449D0
(en)
*
|
1994-12-02 |
1995-01-18 |
Wellcome Found |
Antibodies
|
ATE395422T1
(de)
|
1995-06-07 |
2008-05-15 |
Sanofi Pasteur Ltd |
Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems
|
US6328962B2
(en)
|
1995-06-07 |
2001-12-11 |
Aventis Pasteur Limited |
Method for delivery of antigens to selected cells of the immune system using chimeric antibodies
|
JP4503706B2
(ja)
|
1996-06-07 |
2010-07-14 |
ポニアード ファーマシューティカルズ,インコーポレイティド |
グリコシル化が改質されたヒト化抗体
|
US6475725B1
(en)
|
1997-06-20 |
2002-11-05 |
Baxter Aktiengesellschaft |
Recombinant cell clones having increased stability and methods of making and using the same
|
US20020029391A1
(en)
*
|
1998-04-15 |
2002-03-07 |
Claude Geoffrey Davis |
Epitope-driven human antibody production and gene expression profiling
|
MY133346A
(en)
*
|
1999-03-01 |
2007-11-30 |
Biogen Inc |
Kit for radiolabeling ligands with yttrium-90
|
US20020102208A1
(en)
*
|
1999-03-01 |
2002-08-01 |
Paul Chinn |
Radiolabeling kit and binding assay
|
US7829085B2
(en)
|
1999-07-14 |
2010-11-09 |
Life Sciences Research Partners Vzw |
Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
|
EP2330092A3
(de)
*
|
2000-02-01 |
2012-07-25 |
Stevia APS |
Arzneimittel enthaltend Steviol oder Isosteviol zur Behandlung des Insulinunabhängigen Diabetes Mellitus, Bluthochdruck und/oder des metabolischen Syndroms
|
US6573096B1
(en)
*
|
2000-04-01 |
2003-06-03 |
The Research Foundation At State University Of New York |
Compositions and methods for inhibition of cancer invasion and angiogenesis
|
EP1311269B1
(de)
|
2000-08-04 |
2012-02-29 |
DMI Biosciences, Inc. |
Verfahren zur verwendung von diketopiperazinen und zusammensetzungen, die diese enthalten
|
WO2002062850A2
(en)
*
|
2001-02-02 |
2002-08-15 |
Millennium Pharmaceuticals, Inc. |
Hybrid antibodies and uses thereof
|
US6972324B2
(en)
|
2001-05-18 |
2005-12-06 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Antibodies specific for CD44v6
|
GB0123098D0
(en)
*
|
2001-09-26 |
2001-11-14 |
Lonza Biologics Plc |
Use of aminoglycoside resistance gene
|
US7092957B2
(en)
*
|
2002-01-18 |
2006-08-15 |
Boundary Solutions Incorporated |
Computerized national online parcel-level map data portal
|
US7217796B2
(en)
|
2002-05-24 |
2007-05-15 |
Schering Corporation |
Neutralizing human anti-IGFR antibody
|
JP4836451B2
(ja)
|
2002-07-18 |
2011-12-14 |
メルス ベー ヴェー |
抗体混合物の組換え生産
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
DK1571970T3
(da)
*
|
2002-10-02 |
2011-11-28 |
Dmi Biosciences Inc |
Diagnose og monitorering af sygdomme
|
AU2003274011B2
(en)
|
2002-10-15 |
2010-03-04 |
Intercell Ag |
Nucleic acids coding for adhesion factor of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof
|
PT2301965E
(pt)
|
2002-10-16 |
2015-05-20 |
Purdue Pharma Lp |
Anticorpos que se ligam a ca 125/0722p associado a células e métodos para a sua utilização
|
SI1583830T1
(sl)
|
2003-01-07 |
2006-12-31 |
Symphogen As |
Postopek za pripravo rekombinantnih poliklonskih proteinov
|
US7790399B2
(en)
|
2003-04-03 |
2010-09-07 |
Laboratoire Francais du Fractionnement et des Biotechnolgies (LFB) |
Preparation of human, humanized or chimaeric antibodies or polypeptides having different binding profiles to Fcgamma receptors
|
US8012681B2
(en)
|
2003-05-13 |
2011-09-06 |
Novartis Vaccines And Diagnostics, Inc. |
Methods of modulating metastasis and skeletal related events resulting from metastases
|
JP4422430B2
(ja)
|
2003-05-14 |
2010-02-24 |
帝國製薬株式会社 |
エストロゲン及び/又はプロゲストゲン含有外用貼付剤
|
ES2572975T3
(es)
|
2003-05-15 |
2016-06-03 |
Ampio Pharmaceuticals, Inc. |
Tratamiento de enfermedades mediadas por los linfocitos T
|
WO2004106375A1
(en)
|
2003-05-30 |
2004-12-09 |
Merus Biopharmaceuticals B.V. I.O. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
EP1706079B1
(de)
|
2003-08-14 |
2013-02-20 |
ThromboGenics N.V. |
Antikörper gegen faktor viii mit modifizierter glykosilierung in der variablen region
|
EP1680141B8
(de)
|
2003-11-04 |
2011-01-12 |
Novartis Vaccines and Diagnostics, Inc. |
Verfahren zur behandlung von soliden tumoren mit expression des cd40-zelloberflächen-antigens
|
ATE447412T1
(de)
|
2003-11-04 |
2009-11-15 |
Novartis Vaccines & Diagnostic |
Antagonist-anti-cd40-monoklonale antikörper und anwendungsverfahren
|
EP1844815B1
(de)
|
2003-11-04 |
2011-09-14 |
Novartis Vaccines and Diagnostics, Inc. |
Kombinationstherapie von anti-CD20 und anti-CD40 Antikörpern zur Behandlung von B-Zell-bedingtem Krebs
|
US20070218060A1
(en)
|
2003-11-04 |
2007-09-20 |
Chiron Corporation |
Use of Antagonist Anti-Cd40 Monoclonal Antibodies for Treatment of Multiple Myeloma
|
JP4765037B2
(ja)
|
2003-11-04 |
2011-09-07 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
慢性リンパ球性白血病の処置のためのアンタゴニスト抗cd40モノクローナル抗体の使用
|
AU2005205412B2
(en)
|
2004-01-20 |
2011-08-11 |
Merus N.V. |
Mixtures of binding proteins
|
WO2006125640A2
(en)
*
|
2005-05-24 |
2006-11-30 |
Morphosys Ag |
Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
|
US9200061B2
(en)
|
2004-02-06 |
2015-12-01 |
Morpho Sys AG |
Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
|
CA2555185C
(en)
|
2004-02-06 |
2020-03-24 |
Morphosys Ag |
Anti-cd38 human antibodies and uses therefor
|
WO2006020114A2
(en)
|
2004-08-04 |
2006-02-23 |
Applied Molecular Evolution, Inc. |
Variant fc regions
|
ES2555355T3
(es)
|
2004-09-03 |
2015-12-30 |
Genentech, Inc. |
Antagonistas anti-beta7 humanizados y utilizaciones para los mismos
|
US8137907B2
(en)
|
2005-01-03 |
2012-03-20 |
Cold Spring Harbor Laboratory |
Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
|
US7589182B1
(en)
|
2005-01-07 |
2009-09-15 |
Los Alamos National Security, Llc |
Anti-sulfotyrosine antibodies
|
US8165517B2
(en)
*
|
2005-01-19 |
2012-04-24 |
The Trustees Of The University Of Pennsylvania |
Methods for identifying inhibitors of vascular injury
|
CA2597924C
(en)
*
|
2005-02-15 |
2018-10-02 |
Duke University |
Anti-cd19 antibodies and uses in oncology
|
US8444973B2
(en)
|
2005-02-15 |
2013-05-21 |
Duke University |
Anti-CD19 antibodies and uses in B cell disorders
|
US7595380B2
(en)
|
2005-04-27 |
2009-09-29 |
Tripath Imaging, Inc. |
Monoclonal antibodies and methods for their use in the detection of cervical disease
|
WO2006121852A2
(en)
*
|
2005-05-05 |
2006-11-16 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
EP2312315A1
(de)
|
2005-05-18 |
2011-04-20 |
Novartis AG |
Verfahren zur Diagnose und Behandlung von Krankheiten mit einer autoimmunen und/oder entzündlichen Komponente
|
EP1896587A2
(de)
|
2005-05-31 |
2008-03-12 |
Cold Spring Harbor Laboratory |
Verfahren zur mikro-rna-herstellung
|
EP1904101A4
(de)
*
|
2005-06-08 |
2011-06-15 |
Univ Duke |
Anti-cd19-antikörper-therapie für transplantation
|
AU2006301446B2
(en)
|
2005-10-12 |
2012-06-07 |
Morphosys Ag |
Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
|
WO2007046439A1
(ja)
*
|
2005-10-18 |
2007-04-26 |
National Institute Of Agrobiological Sciences |
抗体を産生するトランスジェニックカイコとその製造方法
|
US7632498B2
(en)
|
2005-12-19 |
2009-12-15 |
Tripath Imaging, Inc. |
MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
|
EP1806365A1
(de)
|
2006-01-05 |
2007-07-11 |
Boehringer Ingelheim International GmbH |
Antikörper spezifisch für Fibroblasten-Aktivierungsprotein und Immunokonjugaten, die diese Antikörper enthalten
|
US20080014203A1
(en)
*
|
2006-04-11 |
2008-01-17 |
Silke Hansen |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
JP2009541208A
(ja)
|
2006-04-13 |
2009-11-26 |
ノバルティス・バクシーンズ・アンド・ダイアグノスティクス・インコーポレイテッド |
がんを処置し、診断しもしくは検出する方法
|
NZ571757A
(en)
|
2006-04-21 |
2012-01-12 |
Novartis Ag |
Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
|
WO2007127936A2
(en)
|
2006-04-27 |
2007-11-08 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
WO2008022152A2
(en)
|
2006-08-14 |
2008-02-21 |
Xencor, Inc. |
Optimized antibodies that target cd19
|
ATE551071T1
(de)
|
2006-09-08 |
2012-04-15 |
Medimmune Llc |
Humanisierte anti-cd19-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
|
MY161866A
(en)
|
2006-09-13 |
2017-05-15 |
Abbvie Inc |
Cell culture improvements
|
US8911964B2
(en)
|
2006-09-13 |
2014-12-16 |
Abbvie Inc. |
Fed-batch method of making human anti-TNF-alpha antibody
|
WO2008043018A1
(en)
|
2006-10-04 |
2008-04-10 |
Dana-Farber Cancer Institute, Inc. |
Tumor immunity
|
JP2010521180A
(ja)
|
2007-03-14 |
2010-06-24 |
ノバルティス アーゲー |
癌を処置、診断または検出するためのapcdd1阻害剤
|
SI2152872T1
(sl)
|
2007-05-25 |
2011-01-31 |
Symphogen As |
Postopek za pripravo rekombinantnega poliklonskega proteina
|
EP2195009B1
(de)
|
2007-09-26 |
2014-07-30 |
Oregon Health and Science University |
Zyklische undekapeptide und derivate als therapien für multiple sklerose
|
EP2300011A4
(de)
|
2008-05-27 |
2012-06-20 |
Dmi Life Sciences Inc |
Therapeutische verfahren und verbindungen
|
DK2349341T3
(da)
*
|
2008-10-15 |
2014-01-06 |
Baxter Int |
Pegylering af rekombinante blodkoagulationsfaktorer i nærvær af bundne antistoffer
|
EP2403880A1
(de)
|
2009-03-05 |
2012-01-11 |
Tripath Imaging, Inc. |
Monoklonale antikörper gegen matrixmetalloproteinase-7 (mmp-7) und verfahren zu ihrer verwendung beim nachweis von eierstockkrebs
|
AU2010221188A1
(en)
|
2009-03-06 |
2011-10-20 |
Tripath Imaging, Inc. |
Glycodelin monoclonal antibodies and methods for their use in the detection of ovarian cancer
|
MX347291B
(es)
|
2009-03-20 |
2017-04-17 |
Amgen Inc |
Inmunoglobulinas portadoras y usos de las mismas.
|
MX342907B
(es)
|
2009-05-13 |
2016-10-17 |
Genzyme Corp * |
El uso de un anticuerpo anti-cd52 monoclonal para el tratamiento de lupus.
|
CA2939492C
(en)
|
2009-05-13 |
2019-03-19 |
Genzyme Corporation |
Anti-human cd52 immunoglobulins
|
JP4525863B1
(ja)
*
|
2009-06-05 |
2010-08-18 |
東洋紡績株式会社 |
高生産性細胞の樹立のための発現ベクター及び高生産性細胞
|
WO2011028390A1
(en)
|
2009-08-24 |
2011-03-10 |
St. Jude Children's Research Hospital |
Compositions and methods for potentiating interleukin-35
|
TW201129379A
(en)
|
2009-11-20 |
2011-09-01 |
Amgen Inc |
Anti-Orai1 antigen binding proteins and uses thereof
|
WO2011063198A2
(en)
|
2009-11-20 |
2011-05-26 |
St. Jude Children's Research Hospital |
Methods and compositions for modulating the activity of the interleukin-35 receptor complex
|
EP2325322A1
(de)
*
|
2009-11-23 |
2011-05-25 |
4-Antibody AG |
Retrovirusvektorpartikel und Verfahren zu deren Erzeugung und Verwendung
|
US8383793B2
(en)
|
2010-04-15 |
2013-02-26 |
St. Jude Children's Research Hospital |
Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors
|
US20140072983A1
(en)
|
2010-08-10 |
2014-03-13 |
Amgen Inc. |
Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
|
US8507496B2
(en)
|
2010-09-07 |
2013-08-13 |
Dmi Acquisition Corp. |
Treatment of diseases
|
EA201370076A1
(ru)
|
2010-09-22 |
2013-08-30 |
Амген Инк. |
Иммуноглобулины-переносчики и их применение
|
US9005907B2
(en)
|
2010-10-01 |
2015-04-14 |
St. Jude Children's Research Hospital |
Methods and compositions for typing molecular subgroups of medulloblastoma
|
WO2012075111A1
(en)
|
2010-11-30 |
2012-06-07 |
Novartis Ag |
Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
|
JP2012125197A
(ja)
*
|
2010-12-16 |
2012-07-05 |
Kyowa Hakko Kirin Co Ltd |
タンパク質の生産方法
|
KR20140009311A
(ko)
|
2011-01-18 |
2014-01-22 |
암젠 인크 |
Nav1.7 넉아웃 마우스 및 이의 용도
|
US20140157443A1
(en)
|
2011-04-14 |
2014-06-05 |
St. Jude Children's Research Hospital |
Methods and compositions for detecting and modulating a novel mtor complex
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
KR20140035967A
(ko)
|
2011-05-26 |
2014-03-24 |
유니버시티 오브 워싱톤 |
세포 및 유전자에 기반한 심장 기능을 개선하는 방법
|
RS55822B1
(sr)
|
2011-09-30 |
2017-08-31 |
Dana-Farber Cancer Institute Inc |
Terapijski peptidi
|
EP3721884A1
(de)
|
2011-10-10 |
2020-10-14 |
Ampio Pharmaceuticals, Inc. |
Behandlung degenerativer gelenkerkrankung mit da-dkp (= aspartly-alanyl-diketopiperazin)
|
US9925300B2
(en)
|
2011-10-10 |
2018-03-27 |
Ampio Pharmaceuticals, Inc. |
Implantable medical devices with increased immune tolerance, and methods for making and implanting
|
WO2013063413A1
(en)
|
2011-10-28 |
2013-05-02 |
Ampio Pharmaceuticals, Inc. |
Treatment of rhinitis
|
EP3559049A4
(de)
|
2011-10-28 |
2019-12-04 |
Teva Pharmaceuticals Australia Pty Ltd |
Polypeptidkonstrukte und anwendungen davon
|
WO2013126813A1
(en)
|
2012-02-22 |
2013-08-29 |
Amgen Inc. |
Autologous mammalian models derived from induced pluripotent stem cells and related methods
|
US9895437B2
(en)
|
2012-04-18 |
2018-02-20 |
Valneva Austria Gmbh |
Aluminum compounds for use in therapeutics and vaccines
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
PT2838917T
(pt)
|
2012-04-20 |
2019-09-12 |
Merus Nv |
Métodos e meios para a produção de moléculas similares a ig heterodiméricas
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
EP2869845B1
(de)
|
2012-07-06 |
2019-08-28 |
Genmab B.V. |
Dimerprotein mit dreifacher mutation
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
US9206390B2
(en)
|
2012-09-02 |
2015-12-08 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
DK2900694T3
(en)
|
2012-09-27 |
2018-11-19 |
Merus Nv |
BISPECIFIC IGG ANTIBODIES AS T-CELL ACTIVATORS
|
EP2722341B1
(de)
|
2012-10-22 |
2017-12-06 |
Fountain Biopharma Inc. |
Antikörper gegen Interleukin-6 und Verwendungen davon
|
WO2014143205A1
(en)
|
2013-03-12 |
2014-09-18 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
US9217168B2
(en)
|
2013-03-14 |
2015-12-22 |
Momenta Pharmaceuticals, Inc. |
Methods of cell culture
|
WO2014159579A1
(en)
|
2013-03-14 |
2014-10-02 |
Abbvie Inc. |
MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
|
CA2906864A1
(en)
|
2013-03-15 |
2014-09-18 |
Ampio Pharmaceuticals, Inc. |
Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
|
US10745483B2
(en)
|
2013-03-15 |
2020-08-18 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
AR095199A1
(es)
|
2013-03-15 |
2015-09-30 |
Genzyme Corp |
Anticuerpos anti-cd52
|
ES2672989T3
(es)
|
2013-03-15 |
2018-06-19 |
Sutter Bay Hospitals |
FALZ para su uso como diana para terapias para tratar el cáncer
|
US11117975B2
(en)
|
2013-04-29 |
2021-09-14 |
Teva Pharmaceuticals Australia Pty Ltd |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
|
AU2013388126B2
(en)
|
2013-04-29 |
2019-03-07 |
Teva Pharmaceuticals Australia Pty Ltd. |
Anti-CD38 antibodies and fusions to attenuated interferon alpha-2b
|
EP3052640A2
(de)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
MX371187B
(es)
|
2013-12-06 |
2020-01-22 |
Dana Farber Cancer Inst Inc |
Péptidos terapéuticos.
|
NZ724013A
(en)
|
2014-02-28 |
2019-11-29 |
Merus Nv |
Antibodies that bind egfr and erbb3
|
WO2015130173A1
(en)
|
2014-02-28 |
2015-09-03 |
Merus B.V. |
Antibody that binds erbb-2 and erbb-3
|
AU2015229009B2
(en)
|
2014-03-14 |
2019-08-22 |
Dana-Farber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring NKG2D pathway function against cancers
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
AU2015264114A1
(en)
|
2014-05-21 |
2016-11-03 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer with anti BiP or anti MICA antibodies
|
JP6723222B2
(ja)
|
2014-08-18 |
2020-07-15 |
アンピオ ファーマシューティカルズ,インコーポレイテッド |
関節病態の治療
|
ES2962385T3
(es)
|
2014-10-15 |
2024-03-18 |
Amgen Inc |
Elementos promotores y reguladores para mejorar la expresión de genes heterólogos en células hospederas
|
KR102639037B1
(ko)
|
2014-10-29 |
2024-02-20 |
테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 |
인터페론 α2b 변이체
|
WO2016209969A1
(en)
|
2015-06-22 |
2016-12-29 |
Ampio Pharmaceuticals, Inc. |
Use of low molecular weight fractions of human serum albumin in treating diseases
|
AU2016293942B2
(en)
|
2015-07-10 |
2022-06-16 |
Merus N.V. |
Human CD3 binding antibody
|
KR20180100305A
(ko)
|
2015-10-23 |
2018-09-10 |
메뤼스 엔.페. |
암 성장을 억제하는 결합 분자
|
CA3058343A1
(en)
|
2017-03-31 |
2018-10-04 |
Merus N.V. |
Erbb-2 and erbb-3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene
|
BR112020002695A2
(pt)
|
2017-08-09 |
2020-08-25 |
Merus N.V. |
anticorpos que se ligam à egfr e cmet
|
JP7230819B2
(ja)
|
2017-10-06 |
2023-03-01 |
小野薬品工業株式会社 |
二重特異性抗体
|
TWI804572B
(zh)
|
2018-02-09 |
2023-06-11 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
TW202102544A
(zh)
|
2019-04-04 |
2021-01-16 |
日商小野藥品工業股份有限公司 |
雙特異性抗體
|
TWI809286B
(zh)
|
2019-07-05 |
2023-07-21 |
日商小野藥品工業股份有限公司 |
以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
|
JP6856183B1
(ja)
|
2019-07-30 |
2021-04-07 |
小野薬品工業株式会社 |
二重特異性抗体
|
TW202120550A
(zh)
|
2019-08-08 |
2021-06-01 |
日商小野藥品工業股份有限公司 |
雙特異性蛋白質
|